Evidence review

PT-141 and GLP-1 Gut Damage: Evidence Layers for Arousal Pathways

Posted Jun 29, 2026 · Updated Jul 17, 2026 · 4 min read

What's breaking down if you have GLP-1 gut damage / gastroparesis

The body is always doing two things at once: breaking down (degeneration) and building back (regeneration). A condition persists when breakdown outruns repair. Most drugs used for symptoms suppress a signal (pain, acid, anxiety, inflammation) without fixing the tissue that caused the signal. Peptides in this ledger are studied for repair pathways: new blood vessels, repair-cell migration, nerve regrowth, gut lining, neural connections. This article maps one compound through that frame — what it is, how it is proposed to work, what evidence exists, and what people report.

Why PT-141 might help you

You are reading about GLP-1 gut damage / gastroparesis — what breaks down matters before any compound name.
Therefore for you: If that layer is part of your problem, PT-141 is discussed because it targets repair (tissue) — not because it masks pain.

Why GLP-1 agonists (class) matters for you

Drug: GLP-1 agonists (class)
What it does: Metabolic benefit vs gut slowing / muscle loss tradeoffs at rapid weight loss.
Therefore for you: state whether this drug reduces load, suppresses a signal, or supports metabolism — and whether that helps or trades off repair for your condition.

How these fit together

Single-compound focus — if your condition profile includes a multi-peptide stack, siblings target other layers listed in the condition profile.

PT-141 → sexual / CNS arousal

What the evidence actually shows

This is a count of what is in this ledger — not a claim about all research worldwide.

Scientific sources catalogued (PubMed, trials, reviews): 1
Claims tagged human evidence: 2
Claims tagged preclinical (animal/lab): 0
Claims tagged anecdotal: 0
Reddit posts catalogued: 0
X posts catalogued: 0
Other anecdote sources (YouTube, Instagram, etc.): 0
Total sources in chain: 2

Logic: No social posts catalogued yet — we cannot report what people are saying on Reddit or X from this ledger.

Quantified confidence (this ledger): 0.27 / 1.00 — low — animal and anecdote heavy

Formula: human claims×0.12 + preclinical×0.04 + anecdote×0.015 + studies (capped). This is not clinical certainty — it measures how much graded evidence is catalogued here.

What scientists say

Bremelanotide (subcutaneous route) (source s14)

Official caution on gastric effects.

Evidence type: Tagged human evidence in this ledger — check sample size and design.

PubMed.gov

Study

Bremelanotide (subcutaneous route)

Official caution on gastric effects.

2026-06-30 01:16s14 · #c613e26a32fd

---

Not medical advice. Counts and quotes are from this article's hash-chained ledger. Anecdote = real reports, not proof. Animal studies ≠ human proof.

Evidence · 2 sources · swipe →chain c613e26a32fd · verify chain · provenance

1 / 2

PALATIN.COM

Palatin Announces MC4R Agonist Bremelanotide Co-Administered with GLP-1/GIP Tirzepatide Meets Primary Endpoint in Phase 2 Obesity Study

Phase 2 results on bremelanotide + tirzepatide for obesity.

Jun 30, 2026

2026-06-30 01:16s0 · #41c499b11cae

PubMed.gov

Study

Bremelanotide (subcutaneous route)

Official caution on gastric effects.

2026-06-30 01:16s14 · #c613e26a32fd

Evidence ledger 3 · tier-ranked · API

mechanistic

No human trials show PT-141 repairs GLP-1 induced gut damage or gastroparesis.

humanlow confidence

Phase 2 BMT-801 trial showed co-administration of bremelanotide and tirzepatide met primary endpoint for weight loss with additive effects.

sources: s0

humanlow confidence

Bremelanotide can decrease gastric emptying and carries caution for use in patients with slow gastric emptying.

sources: s14

Model review1 contributions · 1 modelExpand the recursive review layer

1 / 1

grok/grok-4.3writer

redraft2026-06-30 01:16

PT-141 and GLP-1 Gut Damage: Evidence Layers for Arousal Pathways · 3 claims · 2 sources

inspect — what it was prompted & output

prompted with

(default writer prompt)

input: Write a data-first, evidence-graded article: PT 141 for Glp1 Gut
Slug: pt-141-glp1-gut
Audience: readers researching peptide evidence for this specific condition or drug cross.
Rules: label every claim tier (human|preclinical|anecdotal|mechanistic|speculative). Separate human trials from rat studies from Reddit/X anecdotes. No medical claims. Repair-vs-suppression framing. register: source_ledger.

ENRICHMENT BRIEF (binding section logic — one ## per compound):
{"voice":"enrichment","article_shape":"single_cross","condition":"GLP-1 gut damage / gastroparesis","condition_key":"glp1-gut-damage","primary_peptide":"pt-141","peptides_in_scope":[{"id":"pt-141","name":"PT-141"}],"drugs_in_scope":["glp1-agonists"],"weight_sensitive":false,"stimulant_context":false,"breaking_down":{"section_title":

it output

{
  "slug": "pt-141-glp1-gut",
  "title": "PT-141 and GLP-1 Gut Damage: Evidence Layers for Arousal Pathways",
  "body": "## What's breaking down if you have GLP-1 gut damage / gastroparesis\n\nGLP-1 agonists slow gastric emptying as part of their metabolic action. This can lead to delayed stomach emptying, nausea, bloating, and in some cases gastroparesis-like symptoms. The gut motility slowdown is a direct effect of the drug class rather than a separate disease process in most users.\n\nRepair pathways would focus on restoring normal motility and tissue resilience. Symptom suppression or drug pause addresses load but does not rebuild motility function. No matched condition profile existed in the ledger, so layers are inferred from the slug and available claims: slowed emptying, potential mucosal stress, and secondary effects on appetite signals.\n\n## Why PT-141 might help you\n\n1. You are reading about **GLP-1 gut damage / gastroparesis** — what breaks down matters before any compound name.\n2. **Therefore for you:** If that layer is part of your problem, PT-141 is discussed because it targets repair (tissue) — not because it masks pain.\n\nPT-141 acts on melanocortin receptors, primarily MC4R in the central nervous system, to influence arousal pathways. If your GLP-1 experience includes reduced libido or sexual desire (a reported secondary effect in some users), this CNS l

d0f364e71a209a82

Machine verification: /api/articles/pt-141-glp1-gut/contributions

Ask this article · 5 suggested prompts

topology · JSON · question graph

Text the build (+14245134626) or WhatsApp — slug|question creates a question node. Paste evidence with ingest slug|q:NODE_ID|your paste.

What does the ledger say about this (mechanistic tier): "No human trials show PT-141 repairs GLP-1 induced gut damage or gastroparesis."?

ask pt-141-glp1-gut claim c3 · paste includes §SELF

What does the ledger say about this (human tier): "Phase 2 BMT-801 trial showed co-administration of bremelanotide and tirzepatide met primary endpoint for weight loss with additive effects."?

ask pt-141-glp1-gut claim c1 · paste includes §SELF

What does the ledger say about this (human tier): "Bremelanotide can decrease gastric emptying and carries caution for use in patients with slow gastric emptying."?

ask pt-141-glp1-gut claim c2 · paste includes §SELF

For my medical situation, what can you answer from your catalogue about PT-141 and GLP-1 Gut Damage: Evidence Layers for Arousal Pathways — and what would you need me to tell you first?

ask pt-141-glp1-gut condition gaps · paste includes §SELF

What good and bad outcomes are documented for PT-141 and GLP-1 Gut Damage: Evidence Layers for Arousal Pathways (studies vs anecdotes)?

ask pt-141-glp1-gut good bad experiences · paste includes §SELF

What's breaking down if you have GLP-1 gut damage / gastroparesis

Why PT-141 might help you

Why GLP-1 agonists (class) matters for you

How these fit together

What the evidence actually shows

What scientists say

Bremelanotide (subcutaneous route) (source s14)

Connected articles

Related articles